$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”
Summary
Host Dave Knapp discusses Andrew Dudham’s prediction that GLP-1 prices could drop to $40–$50 monthly, driven by competition and compounding. The episode examines WuXi AppTec’s critical role in the global supply chain, Amilix’s $150,000/year GLP-1 blocker for bariatric hypoglycemia, and Serena Williams’ use of Zepbound in tennis. Knapp also explores anhedonia concerns, optimal dosing strategies, and emerging research on GLP-1s improving male fertility and testosterone levels.
Topics discussed
Intro: Zepbound price predictions and episode overview
Host intro, MyLevel app, and new studio announcement
Andrew Dudham's $40-50 price prediction and market dynamics
WuXi AppTec's role in GLP-1 supply chain and geopolitics
Aveliximab trial for bariatric hypoglycemia
Anhedonia, 'Ozempic face', and dosage discussions
Serena Williams, Zepbound, and GLP-1s in sports
GLP-1s, testosterone, and fertility research
Outro, sponsor ads, and final thoughts
Listen ad-free on Castria